Antimicrobial for 7 or 14 Days for Febrile Urinary Tract Infection in Men: A Multicenter Noninferiority Double-Blind, Placebo-Controlled, Randomized Clinical Trial

被引:1
作者
Lafaurie, Matthieu [1 ,33 ]
Chevret, Sylvie [2 ,3 ]
Fontaine, Jean-Paul [4 ]
Mongiat-Artus, Pierre [5 ]
de Lastours, Victoire [6 ,7 ,8 ]
Escaut, Lelia [9 ]
Jaureguiberry, Stephane [9 ]
Bernard, Louis [10 ]
Bruyere, Franck [11 ]
Gatey, Caroline [12 ,15 ]
Abgrall, Sophie [13 ]
Ferreyra, Milagros [14 ]
Aumaitre, Hugues [14 ]
Aparicio, Caroline
Garrait, Valerie [16 ]
Meyssonnier, Vanina [17 ]
Bourgarit-Durand, Anne [18 ]
Chabrol, Amelie [19 ]
Piet, Emilie [20 ]
Talarmin, Jean-Philippe [21 ]
Morrier, Marine [22 ]
Canoui, Etienne [23 ]
Charlier, Caroline [23 ,24 ]
Etienne, Manuel [25 ]
Pacanowski, Jerome [26 ]
Grall, Nathalie [7 ,8 ,27 ]
Desseaux, Kristell [28 ]
Empana-Barat, Florence [29 ]
Madeleine, Isabelle [30 ]
Bercot, Beatrice [7 ,8 ,31 ]
Molina, Jean-Michel [32 ]
Lefort, Agnes [6 ,7 ,8 ]
机构
[1] Hop St Louis, Hop Lariboisiere, AP HP, Dept Infect Dis, Paris, France
[2] Hop St Louis, Dept Biostat, AP HP, Paris, France
[3] Univ Paris Diderot, Inserm S 717, Paris, France
[4] Hop St Louis, Emergency Dept, AP HP, Paris, France
[5] Hop St Louis, AP HP, Dept Urol, Paris, France
[6] Hop Beaujon, AP HP, Dept Internal Med, Clichy, France
[7] Univ Paris Cite, Infect Antimicrobials Modelling Evolut IAME Res Gr, UMR 1137, Paris, France
[8] Inserm, Paris, France
[9] Hop Bicetre, Dept Infect Dis, AP HP, Le Kremlin Bicetre, France
[10] CHRU Tours, Dept Infect Dis, Tours, France
[11] CHRU Tours, Dept Urol, Tours, France
[12] Hop Antoine Beclere, AP HP, Dept Internal Med, Clamart, France
[13] Univ Paris Saclay, Inserm, U1018, Le Kremlin Bictre, France
[14] Ctr Hosp Perpignan, Dept Infect Dis, Perpignan, France
[15] Hop Lariboisiere, AP HP, Dept Internal Med, Paris, France
[16] Ctr Hosp Intercommunal Creteil, Dept Internal Med, Creteil, France
[17] Grp Hosp Diaconesses Croix St Simon, Dept Internal Med & Infect Dis, Paris, France
[18] Hop Jean Verdier, AP HP, Dept Internal Med, Bondy, France
[19] Hop Sud Francilien, Dept Infect Dis, Corbeil Essonnes, France
[20] Ctr Hosp Annecy Genevois, Dept Infect Dis, Annecy, France
[21] Ctr Hosp Intercommunal Cornouaille, Dept Infect Dis, Quimper, France
[22] Ctr Hosp Dept La Roche Sur Yon, Dept Infect Dis, La Roche Sur Yon, France
[23] Hop Cochin, AP HP, Mobile Infect Dis Team, Paris, France
[24] Univ Paris Cite Hosp, AP HP, French Natl Reference Ctr Listeria, Inst Pasteur,Biol Infect Unit,Inserm,U1117, Paris, France
[25] Hop Charles Nicolle, Dept Infect Dis, Rouen, France
[26] Hop St Antoine, Dept Infect Dis, AP HP, Paris, France
[27] Hop Bichat Claude Bernard, Dept Bacteriol, AP HP, Paris, France
[28] Hop St Louis, Dept Biostat, AP HP, Paris, France
[29] Agence Gen Equipements & Prod St, Clin Trial Dept, AP, Paris, France
[30] Hop St Louis, Pharm, AP HP, Paris, France
[31] Hop St Louis, Hop Lariboisiere, Dept Microbiol, AP HP, Paris, France
[32] Univ Paris Cite, Inserm, UMR 941, Paris, France
[33] Hop St Louis, Infect Dis Dept, 1 Ave Claude Vellefaux, F-75010 Paris, France
关键词
urinary tract infection; men; antibiotic duration; ofloxacin; ANTIBIOTIC-TREATMENT; DURATION;
D O I
暂无
中图分类号
R392 [医学免疫学]; Q939.91 [免疫学];
学科分类号
100102 ;
摘要
In this multicenter randomized, double-blind placebo-controlled noninferiority trial, 240 men were assigned to receive antibiotic therapy for 7 (115 participants) or 14 days (125 participants) for febrile urinary tract infection. A treatment for 7 days was inferior to 14 days. Background The optimal duration of antimicrobial therapy for urinary tract infections (UTIs) in men remains controversial. Methods To compare 7 days to 14 days of total antibiotic treatment for febrile UTIs in men, this multicenter randomized, double-blind. placebo-controlled noninferiority trial enrolled 282 men from 27 centers in France. Men were eligible if they had a febrile UTI and urine culture showing a single uropathogen. Participants were treated with ofloxacin or a third-generation cephalosporin at day 1, then randomized at day 3-4 to either continue ofloxacin for 14 days total treatment, or for 7 days followed by placebo until day 14. The primary endpoint was treatment success, defined as a negative urine culture and the absence of fever and of subsequent antibiotic treatment between the end of treatment and 6 weeks after day 1. Secondary endpoints included recurrent UTI within weeks 6 and 12 after day 1, rectal carriage of antimicrobial-resistant Enterobacterales, and drug-related events. Results Two hundred forty participants were randomly assigned to receive antibiotic therapy for 7 days (115 participants) or 14 days (125 participants). In the intention-to-treat analysis, treatment success occurred in 64 participants (55.7%) in the 7-day group and in 97 participants (77.6%) in the 14-day group (risk difference, -21.9 [95% confidence interval, -33.3 to -10.1]), demonstrating inferiority. Adverse events during antibiotic therapy were reported in 4 participants in the 7-day arm and 7 in the 14-day arm. Rectal carriage of resistant Enterobacterales did not differ between both groups. Conclusions A treatment with ofloxacin for 7 days was inferior to 14 days for febrile UTI in men and should therefore not be recommended.
引用
收藏
页码:2154 / 2162
页数:9
相关论文
共 50 条
  • [21] Vitamin A supplementation is effective for improving the clinical symptoms of urinary tract infections and reducing renal scarring in girls with acute pyelonephritis: a randomized, double-blind placebo-controlled, clinical trial study
    Kahbazi, Manijeh
    Sharafkhah, Mojtaba
    Yousefichaijan, Parsa
    Taherahmadi, Hassan
    Rafiei, Mohammad
    Kaviani, Parisa
    Abaszadeh, Sahand
    Massoudifar, Ali
    Mohammadbeigi, Abolfazl
    COMPLEMENTARY THERAPIES IN MEDICINE, 2019, 42 : 429 - 437
  • [22] Creatine supplementation and resistance training in vulnerable older women: A randomized double-blind placebo-controlled clinical trial
    Gualano, Bruno
    Macedo, Andre Regis
    Rodrigues Alves, Christiano Robles
    Roschel, Hamilton
    Benatti, Fabiana Braga
    Takayama, Liliam
    Pinto, Ana Lucia de Sa
    Lima, Fernanda Rodrigues
    Rodrigues Pereira, Rosa Maria
    EXPERIMENTAL GERONTOLOGY, 2014, 53 : 7 - 15
  • [23] URO-VAXOM(R) AND THE MANAGEMENT OF RECURRENT URINARY-TRACT INFECTION IN ADULTS - A RANDOMIZED MULTICENTER DOUBLE-BLIND TRIAL
    MAGASI, P
    PANOVICS, J
    ILLES, A
    NAGY, M
    EUROPEAN UROLOGY, 1994, 26 (02) : 137 - 140
  • [24] Effect of a sphingolipid-mimetic compound on the promotion of hair growth: A randomized, double-blind, placebo-controlled clinical trial
    Lee, Weon Ju
    Sohng, Chihyeon
    Kim, Jun Young
    Park, Kyung Duck
    Jang, Yong Hyun
    Lee, Seok-Jong
    JOURNAL OF COSMETIC DERMATOLOGY, 2020, 19 (07) : 1715 - 1722
  • [25] Orange Pomace Improves Postprandial Glycemic Responses: An Acute, Randomized, Placebo-Controlled, Double-Blind, Crossover Trial in Overweight Men
    Chen, C. -Y. Oliver
    Rasmussen, Helen
    Kamil, Alison
    Du, Peng
    Blumberg, Jeffrey B.
    NUTRIENTS, 2017, 9 (02):
  • [26] Does ingestion of cranberry juice reduce symptomatic urinary tract infections in older people in hospital? A double-blind, placebo-controlled trial
    McMurdo, MET
    Bissett, LY
    Price, RJG
    Phillips, G
    Crombie, IK
    AGE AND AGEING, 2005, 34 (03) : 256 - 261
  • [27] The effect of magnesium supplementation on primary insomnia in elderly: A double-blind placebo-controlled clinical trial
    Abbasi, Behnood
    Kimiagar, Masud
    Sadeghniiat, Khosro
    Shirazi, Minoo M.
    Hedayati, Mehdi
    Rashidkhani, Bahram
    JOURNAL OF RESEARCH IN MEDICAL SCIENCES, 2012, 17 (12): : 1161 - 1169
  • [28] Antibiotic treatment for 6 days versus 12 days in patients with severe cellulitis: a multicentre randomized, double-blind, placebo-controlled, non-inferiority trial
    Cranendonk, D. R.
    Opmeer, B. C.
    van Agtmael, M. A.
    Branger, J.
    Brinkman, K.
    Hoepelman, A. I. M.
    Lauw, F. N.
    Oosterheert, J. J.
    Pijlman, A. H.
    Sankatsing, S. U. C.
    Soetekouw, R.
    Veenstra, J.
    de Vries, P. J.
    Prins, J. M.
    Wiersinga, W. J.
    CLINICAL MICROBIOLOGY AND INFECTION, 2020, 26 (05) : 606 - 612
  • [29] Efficacy and safety of a new 5% minoxidil formulation in male androgenetic alopecia: A randomized, placebo-controlled, double-blind, noninferiority study
    Blume-Peytavi, Ulrike
    Issiakhem, Zahida
    Gautier, Stephanie
    Kottner, Jan
    Wigger-Alberti, Walter
    Fischer, Tobias
    Hoffmann, Rolf
    Tonner, Francoise
    Bouroubi, Athmane
    Voisard, Jean-Jacques
    JOURNAL OF COSMETIC DERMATOLOGY, 2019, 18 (01) : 215 - 220
  • [30] Targeted Retreatment of Incompletely Recovered Chronic Obstructive Pulmonary Disease Exacerbations with Ciprofloxacin A Double-Blind, Randomized, Placebo-controlled, Multicenter, Phase III Clinical Trial
    Ritchie, Andrew I.
    Brill, Simon E.
    Vlies, Ben H.
    Finney, Lydia J.
    Allinson, James P.
    Alves-Moreira, Luana
    Wiseman, Dexter J.
    Walker, Paul P.
    Baker, Emma
    Elkin, Sarah L.
    Mallia, Patrick
    Law, Martin
    Donaldson, Gavin C.
    Calverley, Peter M. A.
    Wedzicha, Jadwiga A.
    AMERICAN JOURNAL OF RESPIRATORY AND CRITICAL CARE MEDICINE, 2020, 202 (04) : 549 - 557